Omega Therapeutics, Inc. (OMGA)
NASDAQ: OMGA · IEX Real-Time Price · USD
2.410
+0.030 (1.26%)
At close: May 17, 2024, 4:00 PM
2.480
+0.070 (2.90%)
After-hours: May 17, 2024, 7:51 PM EDT
Omega Therapeutics Revenue
Omega Therapeutics had revenue of $4.94M in the twelve months ending March 31, 2024, with 112.70% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $2.36M with 357.36% year-over-year growth. In the year 2023, Omega Therapeutics had annual revenue of $3.09M with 49.25% growth.
Revenue (ttm)
$4.94M
Revenue Growth
+112.70%
P/S Ratio
26.69
Revenue / Employee
$53,108
Employees
93
Market Cap
131.82M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.09M | 1.02M | 49.25% |
Dec 31, 2022 | 2.07M | 1.93M | 1,339.58% |
Dec 31, 2021 | 144.00K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionOMGA News
- 10 days ago - Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers - GlobeNewsWire
- 12 days ago - Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 25 days ago - Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting - GlobeNewsWire
- 5 weeks ago - Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control - GlobeNewsWire
- 7 weeks ago - Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update - GlobeNewsWire
- 2 months ago - Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024 - GlobeNewsWire
- 4 months ago - Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases - GlobeNewsWire
- 4 months ago - Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire